Vasopressin, the antidiuretic hormone, is the major physiologic regulator of renal water excretion and plays an important role in regulating serum osmolality. Several clinical conditions have been associated with inappropriately increased vasopressin secretion that causes antidiuresis, with subsequent retention of water by the kidney.
secretion. Although the osmotic mechanism of regulation of vasopressin secretion is very sensitive, a 15-20% fall in blood pressure is required to induce maximal antidiuresis. Vasopressin release can be influenced by a variety of other factors that are not directly related to osmolal or volume balance. Nausea, hypoglycemia, angiotensin II, nonspecific stress, and acute hypoxia or hypercapnia stimulate vasopressin secretion, whereas drinking lowers plasma vasopressin before there is any appreciable decrease in plasma osmolality. A variety of drugs nicotine, also stimulate or inhibit vasopressin secretion 1) . . The V2R are also present in thick ascending limbs of the loop of Henle and stimulate NaCl reabsorption into the medullary interstitium 3) . They are found in vascular endothelium and effect release of the von Willebrand factor and Factor VIII ( Table 1) .
Vasopressin receptors

The aquaporins
The V2R is a 41 KDa protein of 371 residues with seven transmembrane domains. It is expressed on the plasma Therefore, collecting duct water permeability is regulated by short-term and long-term mechanisms, both critically involving AQP2 4, 5) (Fig. 2) .
Role of vasopressin in hyponatremic states
Plasma vasopressin levels have been found to be in- appropriately elevated in several conditions such as congestive heart failure (CHF), syndrome of inappropriate antidiuretic hormone secretion (SIADH), liver cirrhosis (LC), polycystic kidney disease, nephrotic syndrome, and surgical stress. In SIADH, vasopressin release is not fully suppressed despite hypotonicity. In CHF and LC, a diminished glomerular filtration rate or impaired delivery of solute to the diluting segment impair maximal water excretory capacity. However, the persistence of vasopressin release due to nonosmotic stimuli is predominantly responsible for water retention in these disorders 6) .
Vasopressin receptor antagonists
Vasopressin receptor antagonists (VRAs) was first developed as a peptide antagonist during the 1970s. Although a peptide mediate V2R antagonist effect in animals, a phase 1 trial showed that the agent had a paradoxical weak V2R agonist in human studies. Thus, further development of peptide antagonists was abandoned 7) . .
Conivaptan is a combined V1aR and V2R antagonist, whereas others are selective V2R antagonists. All Agents of this class are inhibitors of the cytochrome P350 3A4
system, but conivaptan is the most potent. In December 2005, the US FDA approved conivaptan for treatment of euvolemic hyponatremia. Although the drug is orally active, to minimize the possibility of drug interaction, the FDA has restricted its distribution to a parenteral form for short-term in-hospital use only. Other VRAs are being Luminal Basolateral .
Congestive heart failure
In the ACTIV in CHF (Acute and Chronic therapeutic
Impact of a Vasopressn Antagonist in Congestive Heart
Failure) trial, 319 hospitalized patients with heart failure exacerbation were randomized to tolvaptan or placebo.
Worsening CHF or unscheduled visits for CHF within 60 days were not different among the treatment groups, although post-hoc analysis suggests that cardiovascular mortality may be reduced in the tolvaptan group in the higher risk group with kidney function impairment or severe congestive findings 11) . Until well-powered studies, to determine whether VRA therapy will have beneficial effect on the CHF neurohormonal cascade have been completed, VRAs are not recommended in patients with CHF.
Liver cirrhosis
Because the presence of portal hypertension in these patients, V1aR blockade may produce hypotension and variceal bleeding owing to antagonism of vasopressin pressor effects in this vascular bed. Thus, only selective V2R antagonists can be recommended for these patients 9) .
Other diseases
A potential role for the VRAs in attenuating polyuria in nephrogenic diabetes insipidus and cyst development in polycystic kidney disease is being explored 9) .
Conclusion
Vasopressin is a neuropeptide hormone that plays an important role in water metabolism via regulation of AQP2
in the principal cells of the renal collecting tubules and connecting tubules. The SIADH, CHF, and LC are among many conditions associated with abnormal water retention mediated by vasopressin release inappropriate to plasma osmolality. VRAs target the cause of abnormal water retention by producing an increase in electrolyte-free water excretion. Thus, these agents will provide highly specific therapy for euvolemic or hypervolemic hyponatremia, CHF, and LC.
